Literature DB >> 6941807

Fluorescence polarization with FDA in leukaemic cells: a clear difference between myelogenous and lymphocytic origins.

H Tsuda, H Maeda, S Kishimoto.   

Abstract

Intracellular fluorescence polarization (IFP) values of normal human lymphocytes and leukaemic cells from newly diagnosed patients were determined from fluorescence polarization using fluorescein diacetate (FDA). Thirty healthy donors and 40 patients with various types of leukaemia (20 myelogenous and 20 lymphocytic) were included in the present studies. The result was that myeloid cells had about twice the polarization value of lymphocytic cells. The use of FDA for the determination of IFP appears to be useful for differential diagnosis, at least between acute myelogenous and lymphocytic leukaemias. These 2 types of leukaemia also showed a pronounced difference in fluorescence intensity when treated with FDA, perhaps owing to a difference in uptake velocity. The previously described membrane microviscosity using 1,6-diphenyl-1,3,5-hexatriene (DPH), however, did not show such a difference between these 2 leukaemias. The fluorescein-binding protein(s) was also investigated in order to clarify its effect on IFP, but there seemed little evidence for the existence of any such dyebinding protein(s). The advantages of the present method, using FDA, reside in its simplicity, rapidity and considerable sensitivity, requiring a small sample of blood usually less than 5 ml.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6941807      PMCID: PMC2010726          DOI: 10.1038/bjc.1981.117

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

2.  Studies on the infectivity and cytopathology of Epstein-Barr virus in human lymphoblastoid cells.

Authors:  F E Durr; J H Monroe; R Schmitter; K A Traul; Y Hirshaut
Journal:  Int J Cancer       Date:  1970-11-15       Impact factor: 7.396

3.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

4.  Cytotoxicity of a factor isolated from human spleen.

Authors:  C B Lozzio; B B Lozzio
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

5.  Microviscosity in the surface membrane lipid layer of intact normal lymphocytes and leukemic cells.

Authors:  M Inbar; M Shinitzky; L Sachs
Journal:  FEBS Lett       Date:  1974-01-15       Impact factor: 4.124

6.  Difference in microviscosity induced by different cholesterol levels in the surface membrane lipid layer of normal lymphocytes and malignant lymphoma cells.

Authors:  M Shinitzky; M Inbar
Journal:  J Mol Biol       Date:  1974-01-05       Impact factor: 5.469

7.  Reaction of fluorescein-isothiocyanate with proteins and amino acids. I. Covalent and non-covalent binding of fluorescein-isothiocyanate and fluorescein to proteins.

Authors:  H Maeda; N Ishida; H Kawauchi; K Tsujimura
Journal:  J Biochem       Date:  1969-05       Impact factor: 3.387

8.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

9.  Treatment of acute leukemia in adults.

Authors:  B D Clarkson; M D Dowling; T S Gee; I B Cunningham; J H Burchenal
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

10.  Terminal deoxynucleotidyl transferase activity in human leukemic cells and in normal human thymocytes.

Authors:  R McCaffrey; T A Harrison; R Parkman; D Baltimore
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.